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endpoint was 6.5% in the BES arm vs 7.1% in the EES arm (pNS). Between the BES
and EES arm no significant differences were observed in cardiac death 0.5% vs 1.3%, MI
4.5% vs 5.4%, TVR 3.5% vs 2.7% and TLR 2.7% vs 2.2, respectively. Definite and
probable stent thrombosis rate was 0.74% in BES and 1.79% in EES (p0.25).
Conclusions: Despite high complexity of lesions in the LL subgroup, good clinical
outcomes and low rate of revascularization were observed at 12 months post-procedure
with both types of drug eluting stents. Stent thrombosis rate was relatively low despite
multiple overlapping stents. Our findings confirm the safety efficacy of both drug-eluting
stents for treatment of patients with long lesions in coronary arteries.
TCT-581
Multislice Computed Tomography Angiography as a Non-invasive
Angiographic and Functional Assessment of the 18-Months Performance of a
Novel Radiolucent Bio-resorbable Coronary Scaffolding Device (ABSORB
Cohort B Trial)
Koen Nieman1, Yoshinobu Onuma2, Robert-Jan van Geuns3, Bernard De Bruyne4,
Leif Thuesen5, Peter Smits6, Jacques Koolen7, Dougal McCLean8,
Bernard Chevalier9, Ian Meredith10, John Ormiston11, Patrick Serruys12
1Thorax Centre, Rotterdam, Netherlands, 2ThoraxCenter, Rotterdam, Rotterdam,
3Erasmus MC, Rotterdam, Netherlands, 4N/A, Aalst, Belgium, 5Department of
Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus, Denmark,
6Maasstad Hospital Rotterdam, Rotterdam, The Netherlands, 7catharina hospital
eindhoven netherlands, Eindhoven, The Netherlands, 8Christchurch Hospital,
Christchurch, New Zealand, 9ICPS, Massy, France, 10Monash University,
Melbourne, Australia, 11Associate Professor, University of Auckland Medical
School, Auckland, New Zealand, 12Professor Interventional Cardiology, Rotterdam,
The Netherlands
Background: To investigate with coronary CT angiography the mid-term outcome of a
percutaneously implanted, bio-resorbable, coronary scaffolding device.
Methods: As part of the ABSORB trial (A Clinical Evaluation of the Bioabsorbable
Everolimus Eluting Coronary Stent System in the Treatment of de Novo Native Coronary
Artery Lesions) 71 patients underwent non-invasive coronary CT angiography 18 months
after implantation of an everolimus eluting, bio-resorbable scaffold (BVS 1.1, Abbott
Vascular, Santa Clara, CA) for treatment of obstructive coronary artery disease. Using
semi-automatic vessel extraction, cross-sectional lumen and vessel areas were measured
at 1-mm longitudinal intervals including 5 mm beyond the scaffold borders. Acquired
MSCT data was further processed for calculation of fractional flow reserve in another
independent corelab (Heart Flow, CA, USA).
Results: At 180 days there were no deaths, three non-Q-wave myocardial infarctions and
four ischemia driven target lesion revascularizations. CT angiographic image quality
allowed qualitative evaluation in 67 patients, and quantitative evaluation in 61 patients.
The mean lumen area within the scaffolded site was 5.1  1.4 mm2, compared to the
7.1-mm2 nominal cross-sectional scaffold area. The average minimal lumen area
measured 3.5  1.0 mm2, and the area stenosis was 23  22% (range -64.2 – 72.0%).
Significant coronary obstruction was qualitatively assessed in a single patient. The mean
plaque area (vessel minus lumen area) measured 8.9  3.4 mm2. Coronary lumen
enlargement up to 13.3 mm2 was observed in one other patient. The non-invasive
functional assessment (functional flow reserve according to MSCT) is ongoing and the
complete results will be presented at the time of meeting.
Conclusions: Noninvasive evaluation by cardiac CT demonstrated good angiographic
results 18 months after implantation of a bio-absorbable coronary scaffolding device. The
feasibility of non-invasive FFR will be presented at the time of meeting.
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Background: The MiStent SES (Micell Technologies, Durham, NC) is an investiga-
tional DES characterized by use of crystalline sirolimus and a fully absorbable polymer
on a thin strut (64um) cobalt-chromium stent. The stent coating is eliminated from the
stent in 45-60 days with full absorption of the polymer by 90 days. The DESSOLVE I FIH
clinical trial was designed to evaluate the initial and long-term efficacy and safety of the
MiStent SES in a defined group of patients.
Methods: The DESSOLVE I FIH clinical trial is a single-arm study conducted at 5
international sites. Thirty patients with discrete de novo lesions (2.5-3.5 mm vessel
diameter and 20 mm length) in native coronary arteries were implanted with a single
MiStent SES. The patients had a primary intervention at either of 4-months, 6-months or
8-months with a subsequent intervention at 18-months. Angiography and IVUS were used
to evaluate the amount of neointimal hyperplasia and stent apposition, and OCT for vessel
healing and stent coverage. Clinical events were assessed at 8-months, 12-months and
18-months.
Results: The initial 4-months, 6-month and 8-month evaluations demonstrated an in-stent
LLL of 0.01, 0.21 and 0.10 respectively as assessed by core laboratory quantitative
angiography. Imaging with OCT demonstrated thin, homogenous coverage with high
rates of stent strut coverage at 6 and 8 months, 93% and 96%, with a low rate of stent strut
malapposition. The IVUS findings supported minimal neointimal hyperplasia with a
neointimal volume index of 0.8mm3/mm at 8 months. Long-term clinical outcomes and
angiographic, OCT and IVUS analyses at 18-months will be presented.
Conclusions: The MiStent SES demonstrates sustained efficacy and safety through 18
months post-procedure.
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Background: To evaluate the safety and effectiveness of the Elixir DESyneTM BD
Novolimus Eluting Coronary Stent System (CSS) with a bioabsorbable polymer com-
pared to the Endeavor Zotarolimus Eluting Coronary Stent System through the assessment
of clinical, angiographic, and IVUS endpoints.
Methods: A total of 149 patients were randomized 3:1, either to the Elixir DESyne BD
Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a
sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the
Endeavor Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of
Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were analyzed
for the primary endpoint of in-stent late lumen loss (LLL) assessed by QCA at 6 months.
Moreover, all patients underwent evaluation for the secondary endpoints including the
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis
at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for
angiographic endpoints at 6 months including: in-segment LLL, percent diameter stenosis,
minimal lumen diameter post-procedure and at 6 months, and angiographic binary
restenosis (ABR) (50%). A subset of patients underwent intravascular ultrasound
(IVUS) evaluation including percent (%) neointimal obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs
7.9%, p0.003). Excellent clinical results at 6 months were demonstrated for both
devices. Clinical results through 12 months and additional angiographic and IVUS results
will be presented.
Conclusions: The study met the primary endpoint demonstrating both non-inferiority
and superiority of the DESyne BD compared to the control. Clinical results through 12
months and complete angiographic and IVUS results will be presented.
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Background: The MiStent SES (Micell Technologies, Durham, NC) is an investiga-
tional drug-eluting stent (DES) developed to address unfavorable late-term outcomes such
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